

WHAT IS CLAIMED IS:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding ESM-1, wherein said
5 antisense compound specifically hybridizes with and inhibits the expression of ESM-1.
2. The antisense compound of claim 1 which is an antisense oligonucleotide.
3. The antisense oligonucleotide of claim 2 comprising a nucleic acid
10 sequence selected from the group consisting of at least eight contiguous bases of SEQ ID NO:1 – SEQ ID NO:2000.
4. The antisense oligonucleotide of claim 2 comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1 – SEQ ID NO:2000.
- 15 5. The antisense compound of claim 2, 3, or 4 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
6. The antisense compound of claim 5 wherein the modified internucleoside linkage is a phosphorothioate linkage.
7. The antisense compound of claim 2, 3, or 4 wherein the antisense
20 oligonucleotide comprises at least one modified sugar moiety.
8. The antisense compound of claim 7 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
9. The antisense compound of claim 2, 3, or 4 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
- 25 10. The antisense compound of claim 9 wherein the modified nucleobase is a 5-methylcytosine.

11. The antisense compound of claim 2, 3, or 4 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
12. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 5 13. The composition of claim 12 further comprising a colloidal dispersion system.
14. The composition of claim 13 wherein the antisense compound is an antisense oligonucleotide.
15. A method of inhibiting the expression of ESM-1 in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so that expression of ESM-1 is inhibited.
- 10 16. A method of treating a human having a disease or condition associated with ESM-1 comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of claim 1 so that expression of ESM-1 is inhibited.
- 15 17. The method of claim 16 wherein the disease or condition is diabetes.
- 20 18. The method of claim 16 wherein the disease or condition is an immunological disorder.
19. The method of claim 16 wherein the disease or condition is a cardiovascular disorder.
20. The method of claim 16 wherein the disease or condition is a neurologic disorder.
- 25 21. The method of claim 16 wherein the disease or condition is ischemia/reperfusion injury.
22. The method of claim 16 wherein the disease or condition is any form of cancer.
- 30 23. The method of claim 16 wherein the disease or condition is an angiogenic disorder.